• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
169968 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  & p+ W1 [2 ]- Z" ^
' T% \8 c; ^8 c& E; K
8 q( L3 U8 T# ?+ A0 ^
Sub-category:
, T8 s" |% z2 P4 t+ vMolecular Targets
) L+ Q3 W5 g- A, y/ e1 s
) K1 Q5 b  z) G" |  V
% B5 v0 T9 f- A5 j' SCategory:& ~: T) w, V+ R9 D6 V
Tumor Biology 0 B4 a" y+ w- j  [5 T  u" |
, W; A; w7 i( E6 S# e
  j/ O9 }; {# \& j+ i
Meeting:( L: w. t0 u' a- U
2011 ASCO Annual Meeting / \# G% H* }# Q- u) x% N
9 k) I6 `) `4 S. U& }5 C
( ]5 k3 |" Y; ?7 L! E5 a0 V
Session Type and Session Title:) F" W* @# `& R* f
Poster Discussion Session, Tumor Biology 5 J6 D! i3 O3 L# L2 a' k
; z: s! D& w+ q4 Z7 ]

: v( L6 t) F8 b' @+ g" SAbstract No:
. e- w. u' _. Q( P5 I5 ?10517 / m! d# Y' ~9 I8 }* f

$ S# }" ?8 N: B! I$ `: n3 _/ k9 b+ R5 S% A5 ~
Citation:
* b  D2 h7 P; rJ Clin Oncol 29: 2011 (suppl; abstr 10517) ! W) o/ R( D) e/ `7 L

0 `1 [. K' V9 c2 ]8 B# G! s  e5 E1 ~4 g  H
Author(s):
8 h$ r# B: e9 b7 l8 h8 ^, ^: gJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China / E0 z, p$ A. A% G

- x7 @) v; \. q5 u# E. Z( M! z/ L) F6 @1 i# n, t2 \

2 M" T/ _% X1 i7 F" w$ ~1 `0 NAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.$ L$ k7 I1 x( M- B: t

, C9 D6 o1 c: S& v: cAbstract Disclosures/ ]5 ~1 D+ z$ f! w2 e) p

: F* T( v. g& B1 z8 \" RAbstract:" D4 i: _- M& @$ {3 }) c- q
, s1 a8 k+ b) h- n, ~7 x( J, Y
3 f; {* n9 ~! H9 I% G! N# h4 g4 n$ r
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
0 Y/ j( a2 G' D( d4 z# d2 W" o8 k5 n8 w+ X+ e/ L: y
/ b- O) P; L; O, T( [1 y
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 1 R% Y% Y$ g( h$ O# ~
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
& m% C) V5 `6 t, T
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 % u" Y! A- M# ?% @
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
0 l  U. Q+ l3 ~7 ?& n" gALK一个指标医院要900多 ...
1 \. F9 E& h3 H4 Y! o
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?- f6 s% O+ ~8 s% C" r$ Z( _
) O1 t/ ^! N8 J8 u$ x3 z
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表